Based on its recent analysis of the global intrauterine device (IUD) market, Frost & Sullivan recognizes OCON Healthcare (OCON) with the 2021 Global Enabling Technology Leadership Award for creating the world’s first and only 3D spherical copper IUD, the Intra Uterine Ball (IUB) Ballerine. The IUD is made from nitinol, a super-elastic alloy that can retain shape and is an ideal transporter of drugs to the uterus to treat various health conditions. The company develops, manufactures, and globally commercializes its technologically superior IUDs based on its proprietary IUB platform.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products, but also enables the development of new products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

“OCON’s flagship product, IUB™ Ballerine, is a hormone-free and flexible birth control device that remains effective for up to five years and has an efficiency rate of more than 99% in preventing pregnancy. Its safety, quality, and comfort advantages have already earned it a global customer base,” said Suchismita Das, Industry Analyst. “IUB™ Ballerine’s small form factor and ‘smartness’ help it easily adapt to the contractions and movements of the uterus, minimizing the risks of damage and irritation associated with conventional T-shaped devices.”

“OCON’s IUB Ballerine and promising SEAD offerings as well as its forward looking pipeline of solutions in development for fibroids, endometriosis, cancers and other hormonal therapies, have positioned it as a pioneer in the conceptualization, development, manufacture, and commercialization of ‘smart’ 3D IUDs,” noted Das. “Its technology is available in 30 countries, including Israel, South Africa, and member countries of the European Union.”

Understanding the myriad of issues women face with rigid T-shaped IUDs, OCON created the IUB™ Ballerine to be uniquely spherical and small (15 mm in diameter). It also demonstrates an improved safety profile, leading to fewer perforations, malposition, and ectopic pregnancies. The device has already received four global regulatory approvals, including Conformité Européenne’s (CE) approval. It is suitable for young women from 15 years of age who wish to delay pregnancy as their fertility is not affected upon removing the device.

Show CommentsClose Comments

Leave a comment